Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 09h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta,...
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
01 avr. 2024 06h00 HE
|
Liquidia Corporation
On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and...
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
13 mars 2024 06h00 HE
|
Liquidia Corporation
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
06 mars 2024 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The...
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
30 janv. 2024 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program...
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
25 janv. 2024 06h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its...
Liquidia Corporation Announces Updates to Operations Leadership
19 janv. 2024 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the...
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
08 janv. 2024 08h22 HE
|
Liquidia Corporation
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
05 janv. 2024 06h45 HE
|
Liquidia Corporation
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...
Liquidia Corporation Announces $100 Million in New Financings
04 janv. 2024 09h10 HE
|
Liquidia Corporation
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing...